13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001940272
Total reported value
$2.2B
$2.2B
256 檔
20.4%
As reported in its official Q4 2025 Form 13F filing, ADAR1 Capital Management, LLC's tracked investment portfolio stood at $2.2B with 256 total positions.
In Q4 2025, ADAR1 Capital Management, LLC displayed an active expansion posture, initiating 60 new positions and adding to 69 existing holdings, outstripping position reductions.
Showing top 200 holdings (of 256 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 13.05% | +1.85% | -2.48% | |
| 2 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 6.73% | -0.78% | +6.06% | |
| 3 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 5.46% | -0.25% | +2.43% | |
| 4 | IMVT | Immunovant Inc | Stock-Other | 4.63% | +0.19% | +10.67% | |
| 5 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.90% | — | +918.59% | |
| 6 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 2.85% | -0.50% | — | |
| 7 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 2.74% | +2.36% | -45.42% | |
| 8 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.52% | -0.66% | +4.09% | |
| 9 | SEPN | Septerna Inc | Stock-Other | 2.37% | -0.10% | -1.60% | |
| 10 | ABUS | Arbutus Biopharma CORP | Stock-Other | 1.91% | -0.55% | +86.52% | |
| 11 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.61% | +1.35% | +43.48% | |
| 12 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.61% | -3.46% | EXIT | |
| 13 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.34% | -0.36% | +5.87% | |
| 14 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.29% | +0.26% | +490.97% | |
| 15 | RAPT | Rapt Therapeutics Inc | Stock-Other | 1.27% | — | +0.38% | |
| 16 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 1.21% | +0.04% | +53.67% | |
| 17 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.20% | +0.19% | -21.94% | |
| 18 | MNPR | Monopar Therapeutics Inc | Stock-Other | 1.12% | +0.07% | +79.93% | |
| 19 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.10% | +0.20% | +216.54% | |
| 20 | PCVX | Vaxcyte Inc | Stock-Other | 1.07% | -0.50% | +48.14% | |
| 21 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.06% | -0.35% | +24.56% | |
| 22 | PRTA | Prothena Corporation plc | Stock-Other | 1.02% | -0.20% | -0.77% | |
| 23 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 1.02% | -0.17% | -9.06% | |
| 24 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.01% | +0.17% | -11.99% | |
| 25 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.97% | — | +177.28% | |
| 26 | IVA | Inventiva SA - Adr | Stock-Other | 0.93% | -0.09% | — | |
| 27 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.92% | +0.02% | +89.02% | |
| 28 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 0.91% | -0.16% | — | |
| 29 | REPL | Replimune Group Inc | Stock-Other | 0.90% | -0.43% | +23.08% | |
| 30 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.85% | -0.11% | +9.95% | |
| 31 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.85% | -0.02% | +4.27% | |
| 32 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.79% | -0.38% | +2.79% | |
| 33 | CGON | Cg Oncology Inc | Stock-Other | 0.79% | -0.35% | +3.70% | |
| 34 | YCY-UN | AA Mission Acquisition Corp. II | Stock-Other | 0.77% | — | — | |
| 35 | TFX | Teleflex Inc | Stock-Healthcare | 0.72% | -0.15% | EXIT | |
| 36 | IWM | Ishares Russell 2000 ETF | ETF-Small Cap | 0.72% | +0.46% | — | |
| 37 | IVVD | Invivyd Inc | Stock-Other | 0.71% | -0.14% | -47.10% | |
| 38 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.68% | +0.08% | -23.24% | |
| 39 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.67% | -0.32% | +7.86% | |
| 40 | EQ | Equillium Inc | Stock-Other | 0.64% | +0.11% | +0.86% | |
| 41 | SVRA | Savara Inc | Stock-Other | 0.62% | -0.07% | -29.31% | |
| 42 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.55% | +0.37% | +589.31% | |
| 43 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.54% | -0.05% | -11.89% | |
| 44 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.53% | -0.03% | — | |
| 45 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.51% | +0.32% | +33256.69% | |
| 46 | BLTE | Belite Bio Inc - Adr | Stock-Other | 0.47% | -0.25% | EXIT | |
| 47 | QURE | uniQure N.V. | Stock-Other | 0.47% | +0.51% | -20.45% | |
| 48 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 0.46% | -0.40% | EXIT | |
| 49 | BHF | Brighthouse Financial Inc | Stock-Financials | 0.45% | -0.06% | +855.23% | |
| 50 | AVR | Anteris Technologies Global | Stock-Other | 0.45% | +0.18% | +526.86% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RNAGBP | Avidity Biosciences Inc | +2.7% | +918.59% | Add |
| 2 | ABVX | Abivax Sa-adr | +2.3% | -2.48% | Trim |
| 3 | 430 | Terns Pharmaceuticals Inc | +1.6% | +5316.15% | Add |
| 4 | IMVT | Immunovant Inc | +1.2% | +10.67% | Add |
| 5 | CLDX | Celldex Therapeutics Inc | +1% | +490.97% | Add |
| 6 | CDTX | Cidara Therapeutics Inc | +0.8% | +177.28% | Add |
| 7 | FULC | Fulcrum Therapeutics Inc | +0.7% | +216.54% | Add |
| 8 | ROIV | Roivant Sciences Ltd. | +0.7% | +2.43% | Add |
| 9 | ABUS | Arbutus Biopharma CORP | +0.7% | +86.52% | Add |
| 10 | ✓ | Establishment Labs Holdings In | +0.6% | +89.02% | Add |
| 11 | PTGX | Protagonist Therapeutics Inc | +0.6% | +6.06% | Add |
| 12 | OVID | Ovid Therapeutics Inc | +0.5% | +33256.69% | Add |
| 13 | REPL | Replimune Group Inc | +0.5% | +23.08% | Add |
| 14 | MAZE | Maze Therapeutics Inc | +0.5% | +589.31% | Add |
| 15 | TARA | Protara Therapeutic Inc | +0.4% | +3127.43% | Add |
| 16 | IKT | Inhibikase Therapeutics Inc | +0.4% | +53.67% | Add |
| 17 | BHF | Brighthouse Financial Inc | +0.4% | +855.23% | Add |
| 18 | CLYM | Climb Bio Inc | +0.4% | +972.77% | Add |
| 19 | AVR | Anteris Technologies Global | +0.4% | +526.86% | Add |
| 20 | PCVX | Vaxcyte Inc | +0.4% | +48.14% | Add |
| 21 | SEPN | Septerna Inc | +0.3% | -1.60% | Trim |
| 22 | SPRY | Ars Pharmaceuticals Inc | +0.3% | +523.96% | Add |
| 23 | ✓ | American Exceptionalism Acqu | +0.3% | +615.08% | Add |
| 24 | RVMD | Revolution Medicines Inc | +0.2% | +4.27% | Add |
| 25 | AGIO | Agios Pharmaceuticals Inc | +0.2% | +408.11% | Add |
| 26 | GUTS | Fractyl Health Inc | +0.2% | +10807.62% | Add |
| 27 | VRTX | Vertex Pharmaceuticals Inc | +0.2% | +95.94% | Add |
| 28 | SRRK | Scholar Rock Holding CORP | +0.2% | +246.44% | Add |
| 29 | CRBP | Corbus Pharmaceuticals Holdi | +0.2% | +2711.58% | Add |
| 30 | TSHA | Taysha Gene Therapies Inc | +0.1% | -11.99% | Trim |
| 31 | URGN | UroGen Pharma Ltd. | +0.1% | +120.50% | Add |
| 32 | CTNM | Contineum Therapeutics Inc-a | +0.1% | +257.82% | Add |
| 33 | CTMX | Cytomx Therapeutics Inc | +0.1% | +5.87% | Add |
| 34 | MNPR | Monopar Therapeutics Inc | +0.1% | +79.93% | Add |
| 35 | ARWR | Arrowhead Pharmaceuticals In | +0.1% | +16.87% | Add |
| 36 | HELP | Cybin Inc | +0.1% | +616.36% | Add |
| 37 | EWTX | Edgewise Therapeutics Inc | +0.1% | +127.50% | Add |
| 38 | GLUE | Monte Rosa Therapeutics Inc | +0.1% | — | Unchanged |
| 39 | CRNX | Crinetics Pharmaceuticals In | +0.1% | +24.56% | Add |
| 40 | PHVS | Pharvaris N.V. | +0.1% | +150.64% | Add |
| 41 | GOSS | Gossamer Bio Inc | +0.1% | +165.60% | Add |
| 42 | OLMA | Olema Pharmaceuticals Inc | +0.1% | +33.00% | Add |
| 43 | MLYS | Mineralys Therapeutics Inc | +0.1% | +74.12% | Add |
| 44 | BIIB | Biogen Inc | +0.1% | +35.00% | Add |
| 45 | ACRS | Aclaris Therapeutics Inc | +0.1% | +64.31% | Add |
| 46 | NRIX | Nurix Therapeutics Inc | +0.1% | +130.99% | Add |
| 47 | JAZZ | Jazz Pharmaceuticals plc | +0.1% | +220.00% | Add |
| 48 | LXEO | Lexeo Therapeutics Inc | +0.1% | -9.06% | Trim |
| 49 | GRCE | Grace Therapeutics Inc | +0.1% | +83.19% | Add |
| 50 | INSP | Inspire Medical Systems Inc | +0.1% | +150.00% | Add |
According to official SEC Form 13F filings, ADAR1 Capital Management, LLC reported a total U.S. public equity portfolio value of $2.2B across 256 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, PTGX, ROIV) accounted for 20.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
IVA
市值: $12.6M
Top Position Liquidated / Trimmed
ETNBGBP
前期市值: $31.1M
During Q4 2025, ADAR1 Capital Management, LLC's top holdings by market value included ABVX (13.1%)、PTGX (6.7%)、ROIV (5.5%). The largest single position, ABVX, represented 13.1% of total portfolio value.
In Q4 2025, ADAR1 Capital Management, LLC made 191 total portfolio adjustments, initiating 60 new buys, adding to 69 positions, trimming 41 holdings, and fully liquidating 21 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.